Jennifer R. Brown, MD, PhD, on Using Venetoclax and Rituximab in Chronic Lymphocytic Leukemia

Posted: Monday, September 16, 2019

How is minimal residual disease negativity used to evaluate the effectiveness of treatments in CLL such as venetoclax plus rituximab?